Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy

Biomarkers

Volumn 16, Issue 1, 2011, Pages 74-82

  Kim, Ki Han ^a   Kwon, Hyuk Chan ^a   Oh, Sung Yong ^a   Kim, Sung Hyun ^a   Lee, Suee ^a   Kwon, Kyung A ^a   Jang, Jin Seok ^a   Kim, Min Chan ^a   Kim, Su Jin ^a   Kim, Hyo Jin ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

5 fluorouracil; cisplatin; ERCC1; Gastric cancer; GSTP1

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; ADVANCED STOMACH CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR VOLUME;

ADULT; AGED; BIOLOGICAL MARKERS; CISPLATIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79251487073     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2010.533284     Document Type: Article

References (29)

1. Baek, S. K., Kim, S. Y., Lee, J. J., Kim, Y. W., Yoon, H. J., Cho K. S. (2006) Increased ERCC Expression Correlates with Improved Outcome of Patients Treated with Cisplatin as an Adjuvant Terapy for Curatively Resected Gastric Cancer. Cancer Res Treat, 38, 19-24.
2. Bouche, O., Ychou, M., Burtin, P., Bedenne, L., Ducreux, M., Lebreton, G., Baulieux, J., Nordlinger, B., Martin, C, Seitz, J. F., Tigaud, J. M., Echinard, E., Stremsdoerfer, N., Milan, C. & Rougier, P. (2005) Adjuvant chemotherapy with 5-fuorouracil and cisplatin com-pared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol, 16, 1488-97.
3. Crew, K. D. & Neugut, A. I. (2006) Epidemiology of gastric cancer. World J Gastroenterol, 12, 354-62.
4. Goekkurt, E., Hoehn, S., Wolschke, C, Wittmer, C, Stueber, C, Hossfeld, D. K. & Stoehlmacher, J. (2006) Polymorphisms of glu-tathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br J Cancer, 94, 281-6.
5. Goto, S., Iida, T., Cho, S., Oka, M., Kohno, S. & Kondo, T. (1999) Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res, 31, 549-58.
6. Harpole, D. H., Jr., Moore, M. B., Herndon, J. E., 2nd, Aloia, T., D,'amico, T. A., Sporn, T., Parr, A., Linoila, I. & Allegra, C. (2001) Te prognos-tic value of molecular marker analysis in patients treated with tri-modality therapy for esophageal cancer. Clin Cancer Res, 7, 562-9.
7. Howie, A. F., Forrester, L. M., Glancey, M. J., Schlager, J. J., Powis, G., Beckett, G. J., Hayes, J. D. & Wolf, C. R. (1990) Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis, 11, 451-8.
8. Johnson, N. P., Hoeschele, J. D. & Rahn, R. O. (1980) Kinetic analysis of the in vitro binding of radioactive cisand trans- dichlorodiammineplatinum(II) to DNA. Chem Biol Interact, 30, 151-69.
9. Kim, J. S., Kim, M. A., Kim, T. M., Lee, S. H., Kim, D. W., Im, S. A., Kim, T. Y., Kim, W. H., Yang, H. K., Heo, D. S., Bang, Y J., Lee, K. U., Choe, K. J. & Kim, N. K. (2009) Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery fol-lowed by adjuvant 5-fuorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favour-able survival. Br J Cancer, 100, 732-8.
10. Kwon, H. C, Roh, M. S., Oh, S. Y., Kim, S. H., Kim, M. C, Kim, J. S. & Kim, H. J. (2007) Prognostic value of expression of ERCC1, thymi-dylate synthase, and glutathione S-transferase P1 for 5-fuorou-racil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol, 18, 504-9.
11. Lim, L., Michael, M., Mann, G. B. & Leong, T. (2005) Adjuvant therapy in gastric cancer. J Clin Oncol, 23, 6220-32.
12. Marsh, S. & Mcleod, H. L. (2004) Cancer pharmacogenetics. Br J Cancer, 90, 8-11.
13. Matsubara, J., Nishina, T., Yamada, Y., Moriwaki, T., Shimoda, T., Kajiwara, T., Nakajima, T. E., Kato, K., Hamaguchi, T., Shimada, Y., Okayama, Y., Oka, T. & Shirao, K. (2008) Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the out-comes of patients with advanced gastric cancer. Br J Cancer, 98, 832-9.
14. Metzger, R., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Lenz, H. J., Hayashi, K., Groshen, S., Salonga, D., Cohen, H., Laine, L., Crookes, P., Silberman, H., Baranda, J., Konda, B. & Leichman, L. (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric can-cer patients receiving combination cisplatin and fuorouracil chemotherapy. J Clin Oncol, 16, 309-16.
15. Monden, N., Abe, S., Sutoh, I., Hishikawa, Y., Kinugasa, S. & Nagasue, N. (1997) Prognostic significance of the expres-sions of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer. Oncology, 54, 391-9.
16. Moscow, J. A., Fairchild, C. R., Madden, M. J., Ransom, D. T., Wieand, H. S., O'brien, E. E., Poplack, D. G., Cossman, J., Myers, C. E. & Cowan, K. H. (1989) Expression of anionic glutathione-S-trans-ferase and P-glycoprotein genes in human tissues and tumors. Cancer Res, 49, 1422-8.
17. Ng, K., Meyerhardt, J. A. & Fuchs, C. S. (2007) Adjuvant and neoadju-vant approaches in gastric cancer. Cancer J, 13, 168-74.
18. Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., Andre, F., Haddad, V, Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., Stahel, R., Sabatier, L., Pignon, J. P., Tursz, T., Le Chevalier, T. & Soria, J. C. (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355, 983-91.
19. Park, D. J. & Lenz, H. J. (2006) Determinants of chemosensitivity in gastric cancer. Curr Opin Pharmacol, 6, 337-44.
20. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. (2005) Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
21. Popat, S., Matakidou, A.?Houlston, R. S. (2004) Tymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol, 22, 529-36.
22. Reed, E. (2005) ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res, 11, 6100-2.
23. Sun, P., Xiang, J. B. & Chen, Z. Y. (2009) Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg, 96, 26-33.
24. Tew, K. D. (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res, 54, 4313-20.
25. Tsuchida, S. & Sato, K. (1992) Glutathione transferases and cancer. Crit Rev Biochem Mol Biol, 27, 337-84.
26. Van Duin, M., De Wit, J., Odijk, H., Westerveld, A., Yasui, A., Koken, M. H., Hoeijmakers, J. H. & Bootsma, D. (1986) Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell, 44, 913-23.
27. Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A. & Fleig, W. E. (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 24, 2903-9.
28. Wilson, M. D., Ruttan, C. C, Koop, B. F. & Glickman, B. W. (2001) ERCC1: a comparative genomic perspective. Environ Mol Mutagen, 38, 209-15.
29. Won, Y. J., Sung, J., Jung, K. W., Kong, H. J., Park, S., Shin, H. R.,Park, E. C, Ahn, Y O., Hwang, I. K., Lee, D. H., Choi, J. S., Kim, W. C, Lee, T. Y., Yoo, C. I., Bae, J. M., Kim, O. N., Chung, W., Kong, I. S. & Lee, J. S. (2009) Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat, 41, 122-31.